文献速递腹部介入技术与安全US

沸腾组织碎化消融离体人肝转移瘤的可行性

Boiling Histotripsy Ex Vivo in Human Liver Metastases of Various Origin.
PubMed 文献 · Ultrasound Med Biol · 2026-06-18

转移瘤硬度显著高于邻近肝实质,坏死性肿瘤在较低脉冲下可被完全消融,而纤维化肿瘤需200脉冲/点才能实现完全碎裂。结果支持沸腾组织碎化用于肝转移瘤的机械消融。

要点

  • 纤维化肝转移瘤完全消融需要高脉冲数,阅片中应关注治疗相关纤维化征象。
  • 坏死性肝转移瘤可用较低脉冲数消融,影像报告中需描述坏死范围。
  • 超声剪切波弹性成像有助于评估肿瘤硬度,辅助消融参数选择。

核心结论

  • 沸腾组织碎化可对多种原发来源的人肝转移瘤实现非侵入性机械消融。
  • 非纤维化或坏死性肿瘤可减少脉冲数以提高消融速度,纤维化肿瘤需要更高脉冲数才能完全碎裂。
  • 研究支持沸腾组织碎化用于肝转移瘤的独立治疗、新辅助治疗或抗肿瘤治疗后残余肿瘤清除。

研究设计与样本

  • 患者年龄39至85岁,中位年龄68岁,原发肿瘤包括结直肠癌、胃癌、乳腺癌和皮肤黑色素瘤。
  • 采用9环2 MHz环形阵列换能器,在实时超声引导下进行沸腾组织碎化。
  • 用剪切波弹性成像测量肿瘤及邻近肝组织的杨氏模量。
  • 治疗网格为1至4层,每层3×3至5×5个点,点间距1 mm,每点25至200脉冲。

关键影像表现/征象

  • 肝转移瘤杨氏模量为44±17 kPa,显著高于邻近肝实质的9.3±3.9 kPa,与肿瘤原发来源无关。
  • 扫描和透射电镜证实肿瘤组织发生亚细胞水平的机械碎裂。

诊断标准与关键数值

  • 坏死性转移瘤在所有试验的沸腾组织碎化方案下均可完全碎裂计划靶区,75脉冲/点时最高治疗速度为54 mm³/min。
  • 纤维化转移瘤仅在200脉冲/点时实现靶区完全碎裂,治疗速度为14 mm³/min;较低脉冲数仅选择性碎裂非纤维化肿瘤成分。

临床应用与阅片要点

  • 超声剪切波弹性成像可用于评估肝转移瘤硬度,为沸腾组织碎化脉冲参数选择提供依据。
  • 对含纤维化的肝转移瘤应优先使用较高脉冲数方案,以保证靶区完全碎裂。
  • 对坏死为主或无纤维化的肝转移瘤可降低脉冲数以加快治疗速度。

局限性

  • 本研究为离体试验,结果尚需体内研究验证。
  • 样本为不同原发来源肝转移瘤但未报告具体各来源例数构成的组间比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: Given the high incidence rate of secondary liver tumors and limitations of the existing treatment options, boiling histotripsy (BH) may provide an incisionless, non-ionizing, ultrasound-guided approach for the mechanical ablation of liver metastases using pulsed high-intensity focused ultrasound waves with shock fronts. This pilot ex vivo study investigated the feasibility of BH for mechanical disintegration of human liver metastases with respect to tumor origin, stiffness, and prior anti-tumor treatment.

METHODS: Eighteen human liver metastases were collected via surgical resection or rapid autopsy from anonymized patients aged 39-85 y (median: 68) with confirmed colorectal, gastric, breast, or skin (cutaneous melanoma) cancers, with or without prior targeted therapy or radiation therapy. The Young's moduli of the tumors and adjacent liver tissue were measured using shear wave elastography. BH was then applied to nodes of a volumetric grid (1-4 layers, 3 × 3 - 5 × 5 points per layer, and 1-mm spacing) at 25-200 pulses per point (1-ms pulses and 1% duty cycle) using a 9-ring 2-MHz annular array under real-time ultrasound guidance. Histological analysis of the treatment outcomes was performed with H&E and Masson's trichrome stains; scanning and transmission electron microscopy were employed for ultrastructural analysis of the fragmented tissue.

RESULTS: Liver metastases were significantly stiffer than the adjacent liver parenchyma (44 ± 17 kPa vs. 9.3 ± 3.9 kPa; p < 9 × 10-5) regardless of tumor origin; these findings are consistent with clinically relevant Young's modulus values reported in prior in vivo studies. In metastases with spontaneous or prior therapy-induced necrosis, all investigated BH protocols successfully disintegrated the planned volumes; the highest treatment rate of 54 mm3/min was achieved using 75 pulses per point. In metastases with therapy-induced fibrosis, complete disintegration of target volumes was achieved only at 200 pulses per point (treatment rate: 14 mm3/min), whereas lower pulse numbers resulted in the selective fragmentation of non-fibrotic tumor components. Electron microscopy confirmed mechanical disintegration of the tumor tissue down to the subcellular level.

CONCLUSION: BH enables non-invasive mechanical ablation of human liver metastases across multiple primary origins. The treatment process can be accelerated by reducing pulse numbers for non-fibrotic or necrotic tumors; however, fibrotic tumors require higher number of BH pulses for complete disintegration. These findings support the use of BH as a potential modality for managing liver metastases, whether applied as a standalone procedure, a neoadjuvant strategy, or following anti-tumor therapy to ensure complete removal of the residual tumor burden.

来源:Ultrasound Med Biol,查看原文。版权归原作者所有。

引用

  1. Ponomarchuk, Tsysar, Sapozhnikov, et al. Boiling Histotripsy Ex Vivo in Human Liver Metastases of Various Origin. Ultrasound Med Biol. 2026. PMID: 42315382. doi:10.1016/j.ultrasmedbio.2026.05.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。